ProSci
Private Company
Funding information not available
Overview
ProSci is a long-established, privately-held provider of essential research reagents, including antibodies and recombinant proteins, serving the global life sciences research and diagnostic markets. The company leverages expertise in protein expression and antibody development to offer a catalog of off-the-shelf products and custom service capabilities. Its business model is based on a service and product sales revenue stream, positioning it as a stable, revenue-generating entity within the broader biotech supply chain. While not a therapeutic developer, ProSci's offerings are fundamental to enabling drug discovery and diagnostic development across the industry.
Technology Platform
Advanced recombinant protein expression systems (prokaryotic and eukaryotic) and antibody generation technologies including hybridoma and phage display, with a focus on rigorous validation for research and diagnostic applications.
Opportunities
Risk Factors
Competitive Landscape
ProSci operates in the fragmented but competitive research antibodies and proteins market. It competes with giants like Thermo Fisher Scientific, Merck Millipore, and Abcam, which have vast catalogs and global distribution, as well as with dozens of specialized boutique reagent providers. Differentiation is primarily achieved through product quality, validation data, customer service, and expertise in difficult-to-express targets.